IDEAS home Printed from https://ideas.repec.org/r/eee/jhecon/v32y2013i1p106-113.html

Mergers and innovation in the pharmaceutical industry

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
  2. Martin Backfisch, 2017. "Have Pharmaceutical R&D Project Success Rates Decreased? A Critical Review and New Empirical Results," MAGKS Papers on Economics 201746, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  3. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  4. Dubois, Pierre & Majewska, Gosia, 2022. "Mergers and Advertising in the Pharmaceutical Industry," CEPR Discussion Papers 17658, Centre for Economic Policy Research.
  5. Hanu Tyagi & Manuel Hermosilla & Rachna Shah, 2025. "Does Transparency Hinder Technological Novelty? Evidence from Large Pharmaceutical Firms," Manufacturing & Service Operations Management, INFORMS, vol. 27(5), pages 1415-1432, September.
  6. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
  7. Hassan Heidari & Arash Refah Kahriz & Yousef Mohammadzadeh, 2019. "Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors," Economic Change and Restructuring, Springer, vol. 52(3), pages 255-277, August.
  8. Liu, Xingyi, 2016. "Vertical integration and innovation," International Journal of Industrial Organization, Elsevier, vol. 47(C), pages 88-120.
  9. Fernando Gascón & Jesús Lozano & Borja Ponte & David Fuente, 2017. "Measuring the efficiency of large pharmaceutical companies: an industry analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(5), pages 587-608, June.
  10. Darren Filson & Saman Olfati & Fatos Radoniqi, 2015. "Evaluating Mergers in the Presence of Dynamic Competition Using Impacts on Rivals," Journal of Law and Economics, University of Chicago Press, vol. 58(4).
  11. Marta F. Arroyabe & Katrin Hussinger & John Hagedoorn, 2020. "Hiring New Key Inventors to Improve Firms’ Post-M&A Inventive Output," DEM Discussion Paper Series 20-19, Department of Economics at the University of Luxembourg.
  12. Wang, Shuxun & Wu, Kai & Lai, Seiwai, 2022. "Acquisition for innovations? M&A intensity and intra-firm innovation reallocations," Research in International Business and Finance, Elsevier, vol. 62(C).
  13. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
  14. Richard J. Gilbert, 2019. "Competition, Mergers, and R&D Diversity," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 54(3), pages 465-484, May.
  15. Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.
  16. Ornaghi, Carmine & Cassi, Lorenzo, 2026. "Acquisitions, inventors’ turnover, and innovation: Evidence from the pharmaceutical industry," European Economic Review, Elsevier, vol. 184(C).
  17. Hiromitsu Goto & Wataru Souma & Mari Jibu & Yuichi Ikeda, 2020. "Multilayer Network Analysis of the Drug Pipeline in the Global Pharmaceutical Industry," Papers 2003.04620, arXiv.org.
  18. Bonnín Roca, Jaime & Vaishnav, Parth & Morgan, M.Granger & Mendonça, Joana & Fuchs, Erica, 2017. "When risks cannot be seen: Regulating uncertainty in emerging technologies," Research Policy, Elsevier, vol. 46(7), pages 1215-1233.
  19. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  20. Jan Malek & Melissa Newham & Jo Seldeslachts & Reinhilde Veugelers, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," Working Papers of Department of Management, Strategy and Innovation, Leuven 735739, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
  21. Tannista Banerjee & Arnab Nayak, 2015. "Comparing Domestic and Cross-Border Mergers and Acquisitions in the Pharmaceutical Industry," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 43(4), pages 489-499, December.
  22. Anthony Pahnke, 2026. "How to Vaccinate a Fish: Merck, the Pharmaceutical Industry and Developing Surveillance Capitalism within the Blue Revolution," Development and Change, International Institute of Social Studies, vol. 57(1), pages 79-102, January.
  23. Jelena Grujić & Slobodan Morača & Angela Fajsi, 2020. "Analysis of Risk Factors in the Channels of Drug Distribution: Professional Perspectives," Sustainability, MDPI, vol. 12(11), pages 1-20, June.
  24. Melanie Büssgen & Tom Stargardt, 2024. "To merge or not to merge? The impact of mergers and acquisitions on corporate success in the pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 45(4), pages 2196-2209, June.
  25. Haucap, Justus & Rasch, Alexander & Stiebale, Joel, 2019. "How mergers affect innovation: Theory and evidence," International Journal of Industrial Organization, Elsevier, vol. 63(C), pages 283-325.
  26. Wolfgang Kerber, 2017. "Rights on Data: Competition, Innovation, and Competition Law: Dissecting the Interplay," MAGKS Papers on Economics 201742, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  27. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.